LEO Pharma Presents New Long-Term Data on Use of Adtralza® (tralokinumab) to Treat Moderate-to-Severe Atopic Dermatitis (AD)
Retrieved on:
Friday, October 13, 2023
Health, Science, Pharmaceutical, Research, Clinical Trials, Congress, European Academy of Occupational Health Psychology, TRACE, Aes, Internal Coordinate Mechanics, Atopic dermatitis, Safety, Eczema Area and Severity Index, LEO, Pneumonia severity index, IGA, AD, ICI, Leo Pharma, Patient, Poster, Pharmaceutical industry, Dermatology, Venereology, Tralokinumab
LEO Pharma A/S, a global leader in medical dermatology, today presented new data assessing the long-term safety and efficacy data of continuous treatment with Adtralza® (tralokinumab) over four years for moderate-to-severe atopic dermatitis (AD) in adults.
Key Points:
- LEO Pharma A/S, a global leader in medical dermatology, today presented new data assessing the long-term safety and efficacy data of continuous treatment with Adtralza® (tralokinumab) over four years for moderate-to-severe atopic dermatitis (AD) in adults.
- The analysis was of participants from ECZTEND who had previously enrolled in the ECZTRA 1 and 2 phase 3 trials.
- Again, the pattern of adverse events (AEs) was consistent with the initial placebo-controlled treatment period and with no new safety signals identified.
- “We aim to use this long-term and real-world evidence to build upon Adtralza’s existing foundation of research.”